Jiangsu Lianhuan Pharmaceutical Co.,Ltd. (600513.SH) announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., recently received the Drug Supplement Approval Notice from the National Medical Products Administration. The notice confirms that Changle Pharmaceutical's Estazolam Tablets have passed the consistency evaluation for generic drug quality and efficacy.
Estazolam Tablets are primarily used to treat anxiety and insomnia, as well as tension, fear, epilepsy, and convulsions. As a commonly prescribed benzodiazepine sedative-hypnotic drug, it plays a significant role in clinical applications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments